Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice


    loading  Checking for direct PDF access through Ovid

Abstract

Background and purpose:Activation of poly(ADP-ribose) polymerase (PARP) is deleterious during cerebral ischemia. We assessed the influence of PARP activation induced by cerebral ischemia on the synthesis of proinflammatory mediators including the cytokines, tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) and the adhesion molecules, E-selectin and intercellular adhesion molecule-1 (ICAM-1).Experimental approach:Ischemia was induced by intravascular occlusion of the left middle cerebral artery for 1 h in male Swiss mice anaesthetized with ketamine and xylazine. The PARP inhibitor PJ34 (1.25–25 mg kg−1) was administered intraperitoneally 15 min before and 4 hours after, the onset of ischemia. Animals were killed 6 h or 24 h after ischemia and cerebral tissue removed for analysis.Key results:Ischemia increased TNF-α protein in cerebral tissue at 6 and 24 h after ischemia. All doses of PJ34 blocked the increase in TNF-α at 6 h and 25 mg kg−1 PJ34 had a sustained effect for up to 24 h. Quantitative real time polymerase chain reaction showed that PJ34 (25 mg kg−1) reduced the increase in TNF-α mRNA by 70% at 6 h. PJ34 also prevented the increase in mRNAs encoding IL-6 (−41%), E-selectin (−81%) and ICAM-1 (−54%). PJ34 (25 mg kg−1) reduced the infarct volume (−26%) and improved neurological deficit, 24 h after ischemia.Conclusions and Implications:PJ34 inhibited the increase in the mRNAs of four inflammatory mediators, caused by cerebral ischemia. The contribution of this effect of PJ34 to neuroprotection remains to be clarified.

    loading  Loading Related Articles